Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11909507 | 0.90 | KDR (0.65) | FGFR3KDR | |
| SCHEMBL3321335 | 0.88 | FGFR3 (0.52) | FGFR3KDR | |
| SCHEMBL3322785 | 0.88 | FGFR3 (0.53) | FGFR3KDR | |
| SCHEMBL3322432 | 0.87 | FGFR3 (0.50) | FGFR3KDR | |
| SCHEMBL20895751 | 0.87 | KDR (0.68) | FGFR3KDR | |
| SCHEMBL3326648 | 0.86 | FGFR3 (0.51) | FGFR3KDR | |
| SCHEMBL11908501 | 0.86 | FGFR3 (0.68) | FGFR3KDR | |
| SCHEMBL3318923 | 0.86 | FGFR3 (0.50) | FGFR3KDR | |
| SCHEMBL11907993 | 0.86 | FGFR3 (0.65) | FGFR3KDR | |
| SCHEMBL3323859 | 0.85 | FGFR3 (0.51) | FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796244-B2 | Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases | ASTEX THERAPEUTICS LTD (GB) | 2014-08-05 | — | — | US | disclosed |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ABL1, ERBB2, RET | FGFR3 82/4885KDR 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.